P4, N=100, Completed, Alexandria University

P3, N=200, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University

P1, N=12, Completed, Engrail Therapeutics INC | Recruiting --> Completed

P=N/A, N=80, Completed, Hasanuddin University

In addition, advanced molecular docking analysis demonstrated strong binding affinity of engeletin with the key regulatory proteins SMAD3 (-9.3 kcal/mol) and NF-κB p65 (-9.1 kcal/mol), providing strong evidence that ENG can directly interact with the central regulators of the TGF-β1/Smad and NF-κB signaling pathways. In conclusion, ENG significantly ameliorated RIS-induced hepatotoxicity, highlighting its potential as hepatoprotective adjuvant therapy.

P2, N=36, Terminated, Austin Hospital | Recruiting --> Terminated

P3, N=510, Recruiting, Jazz Pharmaceuticals | Trial completion date: Aug 2026 --> Jun 2028 | Trial primary completion date: Aug 2026 --> Jun 2028

P2, N=30, Not yet recruiting, Jazz Pharmaceuticals

To evaluate the behavior of pituitary adenomas following cessation of cabergoline (CAB) treatment, postpartum, and postmenopause, in comparison to idiopathic hyperprolactinemia (HPRL)...One untreated idiopathic HPRL case developed a microadenoma 12 months after menopause. HPRL presented a high recurrence rate following CAB discontinuation, regardless of tumor presence or treatment duration, with no reduction in recurrence observed after the postpartum period.

P3, N=227, Active, not recruiting, Alliance for Clinical Trials in Oncology | Recruiting --> Active, not recruiting | N=360 --> 227

P3, N=456, Recruiting, LB Pharmaceuticals Inc. | Not yet recruiting --> Recruiting

This review highlights that, despite the absence of pharmacological agents specifically approved for CAC in the United States and Europe, current guidelines recommend multimodal supportive care, including low-dose olanzapine, nutritional support, and exercise-based interventions. Furthermore, we identify recent phase 2 trials targeting the GDF-15 pathway, such as the GDF-15 inhibitor ponsegromab, which have demonstrated significant improvements in body weight and physical activity, suggesting a potential breakthrough in targeted therapies for CAC...It manifests as a lethal systemic pathology that demands early identification and targeted personalized pharmacological and nutritional interventions. Early diagnosis and targeted intervention represent promising strategies for improving survival and quality of life in this high-risk patient population.